跳至主要内容
临床试验/JPRN-UMIN000018492
JPRN-UMIN000018492尚未招募未知

Effect of minodronate for preventring secondary fragility fractures in postoperative hip fractures of oseteoporotic patients. - Effect of minodronate for preventring secondary fragility fractures in postoperative hip fractures of oseteoporotic patients.

agano Red Cross Hospital0 个研究点目标入组 400 人开始时间: 2015年8月15日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional,observational

入排标准

年龄范围
50years-old 至 100years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Have 3 or more vertebral fractures between L1 and L4 or history of hip fracture. 2.Have peptic ulcers. 3.Have history of gastrectomy or broad gastrointestinal resection. 4.Have diseases that are likely to delay esophageal transit such as esophagus stenosis or achalasia. 5.Cannot keep upright or sitting positioning for 30 minutes or more which taking drug. 6.Have history of severe drug allergy of minodronate or eldecalcitol. 7.Have corrected serum calcium on the latest laboratory result. 8.Have severe hepatic and renal dysfunction and cardiovascular disease. 9.Pregnant females or females who plan to be pregnant. 10.Judged inappropriate to participate the study by attending physicians.

研究者

发起方
agano Red Cross Hospital

相似试验